3710 – GliaDea IgA

Highlights

• Use of recombinant deamidated gliadin
• Ready-to-use (exception: conjugate and wash buffer) and barcoded reagents
• Quality assured handling in routine laboratories
• Incubation at room temperature
• Quantitative determination of IgA antibodies against deamidated gliadin
• Calibrated with internal standard preparationi
• Results expressed in IU/L
• Excellent diagnostic sensitivity and specificity
• High precision within the measurement range
• CE marked
• Automatable

Intended Purpose

The GliaDea IgA is a quantitative immunoassay for the determination of IgA antibodies against deamidated gliadin in human serum. The GliaDea IgA is intended as an aid in the diagnosis of celiac disease in conjunction with other clinical and laboratory findings. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

Celiac disease or gluten-sensitivity is characterized by small intestinal damages leading to a so-called “flat” mucosa. Due to this extensive lesions, malabsorption occurs frequently accompanied with a depletion of key nutrients. The alcohol soluble fraction of gluten, gliadin, a substrate of tissue transglutaminase (tTG), represents a causative agent of celiac disease, by stimulating an inflammatory process in the small intestine. Cellular and humoral immune responses are probably triggered by the cross linking of gliadin into high molecular complexes. Serological method of celiac disease diagnosis includes the detection of IgA and IgG antibodies to tissue transglutaminase and deamidated gliadin. Researchers consider IgA antibodies to tissue transglutaminase the most predictive. For patients with IgA deficiency—a common condition in celiac disease clinicians can use IgG antibodies for diagnosis.

Publications

• Grossmann et al., (2016) Simultaneous detection of celiac disease-specific IgA antibodies and total IgA
• Conrad et al., (2012) A new dot immunoassay for simultaneous detection of celiac specific antibodies and IgA-deficiency